Rosnilimab in moderate to severe ulcerative colitis

Adults with ulcerative colitis diagnosed for more than 90 days and moderate to severe active disease were eligible if they had prior inadequate response, loss of response, or intolerance to at least 2 ulcerative colitis therapy classes. Patients with Crohn's disease or other excluded colitides, rectum-limited disease, prior major bowel surgery, recent intestinal infection, GI dysplasia, prior PD-1/PD-L1 pathway therapy, or excessive prior advanced therapy exposure were excluded.